In August 2022, these guidelines were reviewed by an expert work group convened by ASH.
Review included limited searches for new evidence and discussion of the search results …

Background & Aims Non–vitamin K antagonist oral anticoagulants (NOACs) are convenient
and effective in the prevention and treatment of venous thromboembolism and the …

Background This is the 2nd update to the 9th edition of these guidelines. We provide
recommendations on 17 PICO (Population, Intervention, Comparator, Outcome) questions …

Clinicians have been more and more often encountering patients with venous
thromboembolism (VTE), including pulmonary embolism and deep vein thrombosis, leading …

Background & Aims There is controversy over whether use of non-vitamin K antagonist oral
anticoagulants (NOACs) associates with increased risk of major gastrointestinal bleeding …

Although the incidence of venous thromboembolism (VTE) in Asian populations is lower
than in Western countries, the overall burden of VTE in Asia has been considerably …

Various antithrombotic agents are clinically used to inhibit the cascade of arterial or venous
thrombosis in cardiovascular diseases. Dual antiplatelet therapy with aspirin and P2Y 12 …

Background Direct oral anticoagulants are increasingly used for a wide range of indications.
However, data are conflicting about the risk of major gastrointestinal bleeding with these …

Background Currently, little evidence is available on the length and type of anticoagulation
used for extended treatment for prevention of recurrent venous thromboembolism (VTE) in …

Objective The aim of this study was to determine the severe bleeding safety of direct oral
anticoagulants (DOACs) for the prevention and treatment of venous thromboembolism …